PB60564U\$w

Abstract

The present invention relates to novel compounds of formula (I):

wherein

---- represents a single or a double bond;

R is a radical selected from:

$$i)^{(R_1)p}$$
 $ii)$ $ii)$ $iii)$ $iii)$ $iii)$ $iii)$ $iii)$ and $iv)$ $iii)$

in which R₁ is halogen, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3;

R₂ is hydrogen or C₁₋₄ alkyl;

R₃ is hydrogen, hydroxy or C₁₋₄ alkyl;

R₄ is hydrogen or R₄ together with R₃ represents =0 or =CH2;

R₅ is phenyl, naphthyl, a 9 to 10 membered fused bicyclic heterocyclic group or a 5 or 6 membered heteroaryl group, wherein said groups are optionally substituted by 1 to 3 groups independently selected from trifluoromethyl, C₁₋₄ alkyl, hydroxy, cyano, C₁₋₄ alkoxy, trifluoromethoxy, halogen or S(O)qC₁₋₄ alkyl;

 R_{6} and R_{7} independently are hydrogen, cyano, $C_{1\text{--}4}$ alkyl;

R8 is (CH2)rR10;

Rg is hydrogen, halogen, C_{3-7} cycloalkyl, hydroxy, nitro, cyano or C_{1-4} alkyl optionally substituted by one or two groups selected from halogen, cyano, hydroxy or C_{1-4} alkoxy;

R₁₀ is hydrogen or C₃₋₇ cycloalkyl;

n is 1 or 2;

q is 0, 1 or 2;

r is 0 or an integer from 1 to 4;

PB60564U\$W

or a pharmaceutically acceptable salt or a solvate thereof, process for their preparation and their use in the treatment of conditions mediated by tackykinins and/or by selective inhibition of the serotonin reuptake transporter protein